TNXP Archives - BioTuesdays

Executive Moves

Tonix names Siobhan Fogarty as CTO

Tonix Pharmaceuticals (NASDAQ:TNXP) has announced the appointment of Siobhan Fogarty as chief technical officer (CTO), effective immediately. Previously serving as executive vice president of product development at...

February 4, 2025

Executive Moves

Tonix appoints Gary Ainsworth as VP of market access

Tonix Pharmaceuticals (NASDAQ:TNXP) has announced the appointment of Gary Ainsworth as vice president of market access, effective immediately. Mr. Ainsworth brings extensive pharmaceutical and healthcare consultancy...

January 8, 2025

Developments

Tonix enrolls first patient in Phase 2 study of TX1300 for acute cocaine intoxication

Tonix Pharmaceuticals (NASDAQ:TNXP) announced the first patient dosing in its Phase 2 trial of the recombinant enzyme TNX-1300 for treating life-threatening cocaine intoxication in patients presenting to the emergency...

August 20, 2024

Developments

Tonix fails Phase 2 pain study; holds out hope in fatigue

Tonix Pharmaceuticals Holding’s (NASDAQ:TNXP) TNX-102 SL did not achieve the pre-specified primary endpoint of improving Long COVID pain intensity scores at week 14 in the Phase 2 PREVAIL study. However, TNX-102 showed...

September 5, 2023

Developments

Tonix to acquire 2 FDA-approved migraine products from Upsher-Smith Labs

Tonix Pharmaceuticals (NASDAQ:TNXP) agreed to acquire two currently-marketed products from Upsher-Smith Laboratories: Zembrace SymTouch injection 3 mg, and Tosymra nasal spray 10 mg, for the treatment of acute migraine...

June 26, 2023

Developments

Tonix expedites fibromyalgia and chronic migraine programs

Tonix Pharmaceuticals (NASDAQ:TNXP) is eliminating the interim analyses in its registration-enabling, confirmatory Phase 3 RESILIENT study of TNX-102 SL for fibromyalgia and its Phase 2 PREVENTION study of TNX-1900 for...

April 13, 2023

Developments

Tonix presents positive Phase 3 data in fibromyalgia

Tonix Pharmaceuticals (NASDAQ:TNXP) presented a poster at the 5th International Congress on Controversies in Fibromyalgia in Vienna that its TNX-102 SL met its pre-specified primary endpoint in the Phase 3 RELIEF trial...

March 30, 2023

Developments

Tonix starts Phase 2 intranasal oxytocin study in chronic migraine

Tonix Pharmaceuticals (NASDAQ:TNXP) enrolled the first participant in the Phase 2 PREVENTION study of TNX-1900 (intranasal potentiated oxytocin) for the prevention of chronic migraine headache. The double-blind, placebo...

February 6, 2023

Developments

FDA clears Tonix IND in major depressive disorder

The FDA approved Tonix Pharmaceuticals’ (NASDAQ:TNXP) IND application to support a Phase 2 clinical trial with TNX-601 ER, a once-daily formulation of tianeptine as a potential treatment for major depressive disorder...

October 3, 2022

Developments

Tonix begins Phase 2 trial of TNX-102 SL in Long COVID

Tonix Pharmaceuticals (NASDAQ:TNXP) enrolled the first participant in the Phase 2 PREVAIL study of TNX-102 SL as a potential treatment for a subset of patients with Long COVID syndrome whose symptoms overlap with...

August 22, 2022

Tag - TNXP

Tonix names Siobhan Fogarty as CTO

Tonix appoints Gary Ainsworth as VP of market access

Tonix enrolls first patient in Phase 2 study of TX1300 for acute cocaine intoxication

Tonix fails Phase 2 pain study; holds out hope in fatigue

Tonix to acquire 2 FDA-approved migraine products from Upsher-Smith Labs

Tonix expedites fibromyalgia and chronic migraine programs

Tonix presents positive Phase 3 data in fibromyalgia

Tonix starts Phase 2 intranasal oxytocin study in chronic migraine

FDA clears Tonix IND in major depressive disorder

Tonix begins Phase 2 trial of TNX-102 SL in Long COVID

Subscribe